Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial

Receptor Agonist ◽

Controlled Trial ◽

Randomized Controlled ◽

Glucagon Like Peptide ◽

Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes

10.1111/dom.12802 ◽

2016 ◽

Vol 19 (2) ◽

pp. 200-207 ◽

Cited By ~ 17

Author(s):

Michael A. Nauck ◽

Melanie Kahle ◽

Oleg Baranov ◽

Carolyn F. Deacon ◽

Jens J. Holst

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Controlled Trial ◽

Dipeptidyl Peptidase 4 ◽

Randomized Controlled ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Glucagon Like Peptide ◽

Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial

Diabetes Care ◽

10.2337/diacare.27.6.1335 ◽

2004 ◽

Vol 27 (6) ◽

pp. 1335-1342 ◽

Cited By ~ 218

Author(s):

S. Madsbad ◽

O. Schmitz ◽

J. Ranstam ◽

G. Jakobsen ◽

D. R. Matthews

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Double Blind ◽

Once Daily ◽

Randomized Controlled ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Long Acting

Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial

American Journal of Clinical Nutrition ◽

10.3945/ajcn.115.117440 ◽

2015 ◽

Vol 103 (1) ◽

pp. 66-70 ◽

Cited By ~ 46

Author(s):

Sony S Thazhath ◽

Tongzhi Wu ◽

Michelle J Bound ◽

Helen L Checklin ◽

Scott Standfield ◽

...

Keyword(s):

Type 2 Diabetes ◽

Gastric Emptying ◽

Glycemic Control ◽

Controlled Trial ◽

Randomized Controlled ◽

Glucagon Like Peptide ◽

The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2019.06.009 ◽

2019 ◽

Vol 154 ◽

pp. 101-115 ◽

Cited By ~ 5

Author(s):

Maria Ida Maiorino ◽

Paolo Chiodini ◽

Giuseppe Bellastella ◽

Lorenzo Scappaticcio ◽

Miriam Longo ◽

...

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Randomized Controlled Trials ◽

Receptor Agonist ◽

Meta Analysis ◽

Controlled Trials ◽

Randomized Controlled ◽

Glucagon Like Peptide ◽

The glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide, inhibits small intestinal motility, flow, transit and absorption of glucose in healthy subjects and patients with type 2 diabetes: a randomised controlled trial.

Diabetes ◽

10.2337/db15-0893 ◽

2015 ◽

pp. db150893 ◽

Cited By ~ 7

Author(s):

Sony S. Thazhath ◽

Chinmay S. Marathe ◽

Tongzhi Wu ◽

Jessica Chang ◽

Joan Khoo ◽

...

Keyword(s):

Type 2 Diabetes ◽

Healthy Subjects ◽

Receptor Agonist ◽

Controlled Trial ◽

Small Intestinal Motility ◽

Glucagon Like Peptide ◽

Small Intestinal ◽

Glucagon Like Peptide 1 ◽

Randomised Controlled

A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial

10.1111/dom.12249 ◽

2014 ◽

Vol 16 (6) ◽

pp. 527-536 ◽

Cited By ~ 33

Author(s):

E. M. Brady ◽

M. J. Davies ◽

L. J. Gray ◽

M. A. Saeed ◽

D. Smith ◽

...

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Controlled Trial ◽

Randomized Controlled

Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled

10.1111/dom.12382 ◽

2014 ◽

Vol 16 (12) ◽

pp. 1257-1264 ◽

Cited By ~ 62

Author(s):

J. Reusch ◽

M. W. Stewart ◽

C. M. Perkins ◽

D. T. Cirkel ◽

J. Ye ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Agonist ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Diabetes Care ◽

10.2337/dc16-1957 ◽

2017 ◽

Vol 40 (4) ◽

pp. 614-624 ◽

Cited By ~ 52

Author(s):

Maria Ida Maiorino ◽

Paolo Chiodini ◽

Giuseppe Bellastella ◽

Annalisa Capuano ◽

Katherine Esposito ◽

...

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Combination Therapy ◽

Receptor Agonist ◽

Meta Analysis ◽

Controlled Trials ◽

Randomized Controlled ◽

Glucagon Like Peptide ◽

Metabolic improvement with short‐term glucagon like peptide‐1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients type 2 diabetes: a randomized double‐blind placebo‐controlled trial

10.1111/dom.14480 ◽

2021 ◽

Author(s):

Annemie Stege Bojer ◽

Martin Heyn Sørensen ◽

Jenny Bjerre ◽

Peter Gæde ◽

Niels Vejlstrup ◽

...

Keyword(s):

Type 2 Diabetes ◽

Diastolic Dysfunction ◽

Receptor Agonist ◽

Controlled Trial ◽

Short Term ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing

Diabetes Care ◽

10.2337/dc09-0366 ◽

2009 ◽

Vol 32 (10) ◽

pp. 1880-1886 ◽

Cited By ~ 161

Author(s):

J. Rosenstock ◽

J. Reusch ◽

M. Bush ◽

F. Yang ◽

M. Stewart ◽

...

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Controlled Trial ◽

Randomized Controlled ◽

Monthly Dosing ◽

Long Acting